Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial

What Was Tested

Researchers studied Peptide YY and Ghrelin in this randomized controlled trial publication.

Laparoscopic Roux-en Y-Gastric bypass (LRYGBP) is the commonest available option for the surgical treatment of morbid obesity.

Who Took Part

According to the abstract, 12 patients were involved.

PubMed tags the participants as both men and women.

Twelve patients underwent LRYGBP and 12 patients LRYGBP plus gastric fundus resection (LRYGBP+FR).

All patients were evaluated before and at 3, 6, and 12 months postoperatively.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Peptide YY study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blood samples were collected after an overnight fast and 30, 60, and 120 min after a standard 300-kcal mixed meal.

What Was Measured

PubMed files the paper under topics including Biomarkers, Body Mass Index, Diabetes Mellitus, Type 2, Fasting, Gastric Bypass, Gastric Fundus and Ghrelin.

What This Means in Plain Language

The paper is a randomized study of Peptide YY and Ghrelin in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Obesity surgery), a journal based in United States.

More context: the Peptide YY compound page and the Ghrelin compound page, all human trials.